Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 3:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,641 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Kidney Insufficiency Clear all
Completed Phase 4 Interventional Results available

HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant

NCT02902120
View directory record Official record
Conditions
Hepatitis C, Renal Insufficiency, Chronic, Disorder of Transplanted Kidney
Interventions
Post-transplant Grazoprevir and Elbasvir
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Sep 30, 2026, 3:03 PM EDT
Recruiting No phase listed Observational

A Long-Term Follow-Up Study of Participants Exposed to REACT

NCT05918523
View directory record Official record
Conditions
Diabetic Kidney Disease, Chronic Kidney Diseases
Interventions
Renal Autologous Cell Therapy (REACT)
Biological
Lead sponsor
Prokidney
Industry
Eligibility
30 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Meridian, Idaho
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 30, 2026, 3:03 PM EDT
Completed Phase 4 Interventional Results available

Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)

NCT00908310
View directory record Official record
Conditions
Chronic Kidney Disease, Renal Insufficiency
Interventions
Omniscan
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Sep 30, 2026, 3:03 PM EDT
Completed Not applicable Interventional

Hospital-Level Care at Home for Acutely Ill Adults

NCT03203759
View directory record Official record
Conditions
Infection, Heart Failure, COPD, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions
Home hospitalization, Traditional inpatient hospitalization
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Sep 30, 2026, 3:03 PM EDT
Completed Phase 4 Interventional Results available

KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)

NCT03236246
View directory record Official record
Conditions
Chronic Kidney Diseases, Iron Deficiency Anemia
Interventions
KRX-0502
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
28
States / cities
Phoenix, Arizona • Chula Vista, California • El Centro, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2021 · Synced Sep 30, 2026, 3:03 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Twice Weekly Hemodialysis in Patients With Residual Kidney Function

NCT03874117
View directory record Official record
Conditions
Hemodialysis, Kidney Failure, Chronic
Interventions
Twice Weekly Hemodialysis then Thrice Weekly Hemodialysis, Thrice Weekly Hemodialysis then Twice Weekly Hemodialysis
Other
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Palo Alto, California • San Jose, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Sep 30, 2026, 3:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered by Intravenous Infusion Investigational Intervention in Participants Aged 35 to 75 Years of Age With Chronic Kidney Disease (CKD)

NCT06721143
View directory record Official record
Conditions
Chronic Kidney Disease Stage 3
Interventions
AION-301, Placebo
Biological · Drug
Lead sponsor
AION Healthspan, Inc.
Industry
Eligibility
35 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 30, 2026, 3:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients

NCT00183248
View directory record Official record
Conditions
Kidney Transplantation, Kidney Disease, Kidney Failure
Interventions
Alemtuzumab, Mycophenolate mofetil, Sirolimus, Tacrolimus, Donor bone marrow stem cell infusion, Kidney transplant
Drug · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 2, 2012 · Synced Sep 30, 2026, 3:03 PM EDT
Recruiting No phase listed Observational

Drug Interaction Potential of Pro-Inflammatory Conditions

NCT07360938
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, End Stage Renal Disease, Irritable Bowel Syndrome
Interventions
None (Observational)
Other
Lead sponsor
Indiana University
Other
Eligibility
12 Years to 99 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 30, 2026, 3:03 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Severe Sepsis in Children - IMPRESS-C

NCT02598674
View directory record Official record
Conditions
Acute Kidney Injury, Chronic Kidney Disease, Hypertension
Interventions
Iodohippurate, 24 hour ambulatory Blood Pressure, Peripheral Arterial Tonometry, Pulse Wave Velocity, Gadolinium
Drug · Procedure
Lead sponsor
University of Florida
Other
Eligibility
7 Years to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Sep 30, 2026, 3:03 PM EDT
Completed Phase 3 Interventional Results available

Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis

NCT02341417
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
Cinacalcet
Drug
Lead sponsor
Amgen
Industry
Eligibility
Up to 18 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
18
States / cities
Los Angeles, California • Tucker, Georgia • Baltimore, Maryland + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Sep 30, 2026, 3:03 PM EDT
Completed Phase 2 Interventional

Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934

NCT01975818
View directory record Official record
Conditions
Anemia, Renal Insufficiency, Chronic
Interventions
Molidustat (BAY 85-3934), Epoetin alfa/beta
Drug · Biological
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
30
States / cities
Azusa, California • Long Beach, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Sep 30, 2026, 3:03 PM EDT
Completed No phase listed Observational

Effect of Viscous Fiber on Postprandial Kalemic Response in Hemodialysis Patients

NCT05086185
View directory record Official record
Conditions
Hyperkalemia, Chronic Kidney Disease Requiring Chronic Dialysis
Interventions
Kalemic Response to Orange Juice, Kalemic Response to Orange Juice with Fiber
Diagnostic Test · Dietary Supplement
Lead sponsor
University of Nevada, Reno
Other
Eligibility
18 Years to 89 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 30, 2026, 3:03 PM EDT
Completed No phase listed Observational

Smarter Care Virginia, Examining Low-Value Care in Virginia

NCT04053335
View directory record Official record
Conditions
Chronic Kidney Diseases, Eye Diseases, Cardiac Disease, Surgery, Low Back Pain
Interventions
Multicomponent Physician Performance Peer-Comparison Feedback Intervention
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
5,000,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Sep 30, 2026, 3:03 PM EDT
Recruiting No phase listed Observational

Partners Calciphylaxis Biobank

NCT03032835
View directory record Official record
Conditions
Calciphylaxis, Calcific Uremic Arteriolopathy, End Stage Renal Disease, Chronic Kidney Diseases
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 30, 2026, 3:03 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)

NCT05092347
View directory record Official record
Conditions
Chronic Kidney Disease (CKD)
Interventions
Vonsetamig
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 30, 2026, 3:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Peer-mentoring, Quality of Life and Caregiver Burden in Patients With Chronic Kidney Disease and Their Caregivers

NCT02429115
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Mentoring
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Harrisburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Sep 30, 2026, 3:03 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

NCT02865850
View directory record Official record
Conditions
Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
54
States / cities
Huntsville, Alabama • Mesa, Arizona • Anaheim, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Sep 30, 2026, 3:03 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive

NCT00800683
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 1356, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
24
States / cities
Phoenix, Arizona • Chula Vista, California • Riverside, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Sep 30, 2026, 3:03 PM EDT
Active, not recruiting Not applicable Interventional

Improving Medical Decision Making for Older Patients With End Stage Renal Disease

NCT04347629
View directory record Official record
Conditions
Renal Disease, End Stage, Palliative Care, Decision Aids
Interventions
Advance Care Planning Video Decision Aid
Behavioral
Lead sponsor
Tufts Medical Center
Other
Eligibility
65 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
9
States / cities
Palo Alto, California • Boston, Massachusetts • Springfield, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 30, 2026, 3:03 PM EDT
Recruiting Not applicable Interventional

Deceased Donor Kidney Storage at 10 Celsius Versus Conventional Storage

NCT07385651
View directory record Official record
Conditions
End Stage Chronic Renal Failure, Chronic Kidney Disease (Stages 4 and 5), Kidney Transplantation Recipients
Interventions
10˚C deceased donor kidney storage using Traferox XPort
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 30, 2026, 3:03 PM EDT
Completed Phase 2Phase 3 Interventional

African American Study of Kidney Disease and Hypertension ABPM Pilot Study

NCT00582777
View directory record Official record
Conditions
Hypertensive Renal Disease
Interventions
USUAL - take your BP Meds as you usually do, HS DOSING, ADD On Dosing
Behavioral · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2012 · Synced Sep 30, 2026, 3:03 PM EDT
Terminated Phase 2 Interventional Results available

Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD)

NCT02525263
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes
Interventions
Neo-Kidney Augment
Biological
Lead sponsor
Prokidney
Industry
Eligibility
30 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Sep 30, 2026, 3:03 PM EDT
Completed No phase listed Observational

Insulin Dosing in Diabetic Patients With End Stage Renal Disease (ESRD) or Hemodialysis

NCT02083133
View directory record Official record
Conditions
Diabetes, Hypoglycemia, Renal Dysfunction, Insulin Dosing
Interventions
Not listed
Lead sponsor
Cook County Health
Government
Eligibility
18 Years to 99 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Sep 30, 2026, 3:03 PM EDT